MILAN, April. 2 (Class Editori) - Menarini Diagnostics and the company Credo Diagnostics Biomedical based in Singapore have signed an agreement for the exclusive distribution of new kits, which allow to diagnose COVID-19 in 20 minutes.
After the medical staff has taken a nose/oropharyngeal sample, this is inserted in a vial containing a liquid and then shaken. Its content will then be poured in another vial, which contains the reagent. Once the vial is closed, it will be inserted inside the VitaPCr system (the tool of Point Of Care for molecular diagnostic by Credo Diagnostics Biomedical), to start the analysis process. In less than half an hour, the tool, already CE marked, will release the result on its screen, by showing the positivity or negativity of the analysed sample.
The COVID-19 test is fundamental for structures where patients are firstly received as well as for Intensive Care Units. These SARS-COV-2 kits, together with other tests needed to detect respiratory infections (RSV and Strep A group) and also thanks to their dimensions, comparable to those of a dictionary, allow an immediate diagnosis in contexts such as emergency departments, triage tents, airports, harbours, railway stations.
"We have always believed that the Point of Care tests with molecular diagnostics represent the future. We are glad to be able to collaborate with Menarini, in order to make these tests available and save lives, in particular in such a critical moment", Winston Wong Jr., chairman of Credo Diagnostics Biomedical has declared.
"During these last weeks, Menarini Diagnostics has worked hard to provide support to health professionals in order to cope with the virus" as Fabio Piazzalunga, General Director of Menarini Diagnostics, has stated. "We believe it is fundamental to have solutions which will allow the diagnosis of positive cases by reducing times as much as possible, bringing the screening where it is needed and then quickly implementing it with accurate technologies. Thanks to the collaboration with Credo Diagnostic Biomedical, Menarini Group is hoping to give a significant support to the health professionals."
Singapore is one of the Asian strongholds of the company from Florence. The aim is reaching a 1 billion turnover in the area by 2022, according to what Luca Castrucci who is responsible for the Asia-Pacific area stated one year ago. The year 2011 has represented the turning point in this area, when, thanks to a "flash" operation, the group acquired Invida, a company which was active in 13 countries of the area and was afterwards renamed Menarini Asia-Pacific.
The main market is the Chinese one. In terms of importance, the second of the area is the Indian one, the largest pharmacy worldwide, which multinational corporations are encouraged to join thanks to the consumption dimensions and the low production costs, -30 percent compared to the USA. However, the Made in India is affected by a low production standard and the foreign multinational corporation may contribute to the improvement of this perception.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.